Report No. 8/2026 Results from long-term observation of patients in the clinical trial of the product BCX-CM-AD intended for the treatment of atopic dermatitis in dogs

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer”, the “Company”), with reference to current report ESPI No. 19/2025 dated August 12, 2025 informing about the final results of the clinical trial regarding the safety and efficacy of the product BCX-CM-AD in the treatment of atopic dermatitis in […]

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.